Drug Name: Orserdu Indications: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine…
Drug Name: Leqembi Indications: To treat Alzheimer’s disease Active Ingredient: Lecanemab-irmb Company: Eisai Inc Approval Date: 1/6/2023 More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf
Drug Name: Brenzavvy Indications: To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Active Ingredient: Bexagliflozin Company: TheracosBio, LLC Approval…
Drug Approval Name: Briumvi Active Ingredient: ublituximab-xiiy Indications: To treat relapsing forms of multiple sclerosis Approval Date: 12/28/2022 Company: TG Therapeutics, Inc. Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf
Name: NexoBrid Active Ingredient: anacaulase-bcdb Indications: To remove eschar in adults with deep partial thickness or full thickness thermal burns Approval Date: 12/28/2022 Company: MediWound LTD Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761192s000lbl.pdf
Drug Name: Sunlenca Active Ingredient: lenacapavir Indications: To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations…
Drug Name: Lunsumio Active Ingredient: mosunetuzumab-axgb Indications: To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma Approval Date: 12/22/2022 Company: Genentech, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf
Drug Name: Krazati Active Ingredient: adagrasib Indications: To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy…
Drug Name: Rezlidhia Active Ingredient: olutasidenib Indications: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation Approval Date: 12/1/2022 Company: Forma Therapeutics,…
Drug Name: Tzield Active Ingredient: teplizumab-mzwv Indications: To delay the onset of stage 3 type 1 diabetes Approval Date: 11/18/22 Company: Provention Bio, Inc. (a Sanofi company) Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf